APBB2
Amyloid-beta A4 precursor protein-binding family B member 2
Protein Summary
May modulate the internalization of amyloid-beta precursor protein. The protein encoded by this gene interacts with the cytoplasmic domains of amyloid beta (A4) precursor protein and amyloid beta (A4) precursor-like protein 2. This protein contains two phosphotyrosine binding (PTB) domains, which are thought to function in signal transduction. Polymorphisms in this gene have been associated with Alzheimer's disease. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]
- ENST00000295974
- ENSP00000295974
- ENSG00000163697
- ENST00000502841
- ENSP00000425802
- ENST00000504305
- ENSP00000423765
- ENST00000508593
- ENSP00000427211
- ENST00000513140
- ENSP00000426018
- ENST00000543538
- ENSP00000439357
- FE65L
- FE65L1
- FE65L
- FE65L1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.99 | ||
kinase perturbation | 0.95 | ||
transcription factor binding site profile | 0.93 | ||
microRNA | 0.92 | ||
PubMedID | 0.82 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 21.12 (req: < 5)
Gene RIFs: 16 (req: <= 3)
Antibodies: 159 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 21.12 (req: >= 5)
Gene RIFs: 16 (req: > 3)
Antibodies: 159 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 11
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0